Enzyme market projected to reach $28.7 billion by 2030

The global enzyme market is projected to experience significant growth, rising from an estimated $15.2 billion in 2025 to $28.7 billion by 2030. This expansion is driven by increasing cancer incidence rates, which boost demand for drug-metabolizing enzymes used in chemotherapy, as well as advancements in microbial fermentation and biotechnology research.

Key market drivers include the development of enzyme-based therapies for various conditions, ranging from leukemia and gastric diseases to rare genetic disorders like Gaucher and Fabry diseases. North America remains the largest market for these technologies. The sector is also benefiting from progress in protein engineering, personalized medicine, and the adoption of enzyme-based diagnostic technologies.

Notable industry developments include AstraZeneca’s $1.3 billion acquisition of CinCor Pharma to strengthen its enzyme-based pipeline, and Kyowa Global Rare Disease receiving FDA approval for Lamzede, a first-of-its-kind enzyme replacement therapy for non-neurological symptoms of alpha-mannosidosis.